Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

TY - JOUR

T1 - Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

AU - Coleman, Robert L.

AU - Moon, James

AU - Sood, Anil K.

AU - Hu, Wei

AU - Delmore, James E.

AU - Bonebrake, Albert J.

AU - Anderson, Garnet L.

AU - Chambers, Setsuko K.

AU - Markman, Maurie

N1 - Keywords: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Cancer, Chemotherapy, Taxanes, Vandetanib, Clinical Trial, Randomized phase II Ovarian cancer is the leading cause of death from gynecologic malignancy and the fifth leading cause of cancer death in American women.

PY - 2014/6/1

Y1 - 2014/6/1

UR - http://europepmc.org/articles/PMC4098779

U2 - 10.1016/J.EJCA.2014.03.005

DO - 10.1016/J.EJCA.2014.03.005

M3 - Article

VL - 50

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 9

ER -